Lipid-Polymer Hybrid Nanoparticles for Topical Drug Delivery System
Abstract
Human skin not only functions as a permeation barrier (mainly due to the stratum corneum layer), but also provides a unique delivery pathway for therapeutic and other active agents. These compounds penetrate via intercellular, intracellular and transappendageal routes, resulting in topical delivery (into skin strata) and transdermal delivery (to subcutaneous tissues and into the systemic circulation). Lipid–polymer hybrid nanoparticles (LPHNPs) are next-generation core–shell nanostructures, conceptually derived from both liposome and polymeric nanoparticles (NPs), where a polymer core remains enveloped by a lipid layer. Although they have garnered significant interest, they remain not yet widely exploited or ubiquitous. Recently, a fundamental transformation has occurred in the preparation of LPHNPs, characterized by a transition from a two-step to a one-step strategy, involving synchronous self-assembly of polymers and lipids. Owing to its two-in-one structure, this approach is of particular interest as a combinatorial drug delivery platform in oncology. In particular, the outer surface can be decorated in multifarious ways for active targeting of anticancer therapy, delivery of DNA or RNA materials, and use as a diagnostic imaging agent.
Keywords: Lipid–polymer hybrid nanoparticle, Topical delivery, Drug delivery, Gene delivery.
Keywords:
Lipid–polymer hybrid nanoparticle, Topical delivery, Drug delivery, Gene deliveryDOI
https://doi.org/10.22270/jddt.v13i4.5789References
Farokhzad O, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006; 58(14):1456-1459. https://doi.org/10.1016/j.addr.2006.09.011
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1):20-37. https://doi.org/10.1038/nrc.2016.108
Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5(3):161-171. https://doi.org/10.1038/nrc1566
Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010; 363(25):2434-2443. https://doi.org/10.1056/NEJMra0912273
Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012; 41(7):2971-3010. https://doi.org/10.1039/c2cs15344k
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlledrelease polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016; 116(4):2602-2663. https://doi.org/10.1021/acs.chemrev.5b00346
Nair SS, Chitosan-based transdermal drug delivery systems to overcome skin barrier functions, Journal of Drug Delivery and Therapeutics. 2019; 9(1):266-270 https://doi.org/10.22270/jddt.v9i1.2180
Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012; 14(1):1-16. https://doi.org/10.1146/annurev-bioeng-071811-150124
Cho EJ, Holback H, Liu KC, Abouelmagd SA, Park J, Yeo Y. Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm. 2013; 10(6):2093-2110. https://doi.org/10.1021/mp300697h
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-515. https://doi.org/10.1021/mp800051m
Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol. 2010; 28(12):1267-1270. https://doi.org/10.1038/nbt.1725
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3(1):16-20. https://doi.org/10.1021/nn900002m
Jain S, Kirar M, Bindeliya M, Sen L, Soni M, Shan M, Purohit A, Jain PK, Novel drug delivery systems: an overview. Asian J Dent Health Sci. 2022; 2(1):33-39 https://doi.org/10.22270/ajdhs.v2i1.14
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20-37. https://doi.org/10.1038/nrc.2016.108
Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010; 363(25):2434-2443. https://doi.org/10.1056/NEJMra0912273
Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5(3):161-171. https://doi.org/10.1038/nrc1566
Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2(8): 1696-1702. https://doi.org/10.1021/nn800275r
Wakaskar RR. General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 2018; 26(4):311-318. https://doi.org/10.1080/1061186X.2017.1367006
Fang RH, Aryal S, Hu CM, Zhang L. Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir. 2010; 26(22):16958-16962. https://doi.org/10.1021/la103576a
Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2):117-134. https://doi.org/10.1016/j.jconrel.2012.03.020
Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013; 9(4):474-491. https://doi.org/10.1016/j.nano.2012.11.010
Thevenot J, Troutier AL, David L, Delair T, Ladavière C. Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules. 2007; 8(11):3651-3660. https://doi.org/10.1021/bm700753q
Mieszawska AJ, Gianella A, Cormode DP, et al. Engineering of lipidcoated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb). 2012; 48(47):5835-5837. https://doi.org/10.1039/c2cc32149a
Fenart L, Casanova A, Dehouck B, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther. 1999; 291(3):1017-1022.
Cserr HF, Ostrach LH. Bulk flow of interstitial fluid after intracranial injection of blue dextran 2000. Exp Neurol. 1974; 45(1):50-60. https://doi.org/10.1016/0014-4886(74)90099-5
Wang H, Zhao P, Su W, et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials. 2010; 31(33):8741-8748. https://doi.org/10.1016/j.biomaterials.2010.07.082
Troutier AL, Delair T, Pichot C, Ladavière C. Physicochemical and interfacial investigation of lipid/polymer particle assemblies. Langmuir. 2005; 21(4):1305-1313. https://doi.org/10.1021/la047659t
Hitzman CJ, Elmquist WF, Wattenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci. 2006; 95(5):1114-1126. https://doi.org/10.1002/jps.20591
Li X, Anton N, Arpagaus C, Belleteix F, Vandamme TF. Nanoparticles by spray drying using innovative new technology: the Büchi nano spray dryer B-90. J Control Release. 2010; 147(2):304-310. https://doi.org/10.1016/j.jconrel.2010.07.113
Bershteyn A, Chaparro J, Yau R, et al. Polymer-supported lipid shells, onions, and flowers. Soft Matter. 2008; 4(9):1787-1791. https://doi.org/10.1039/b804933e
Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces. 2011; 85(2):214-220. https://doi.org/10.1016/j.colsurfb.2011.02.033
Li Y, Wong HL, Shuhendler AJ, Rauth AM, et al., Molecular interactions, internal structure and drug release kinetics of rationally developed polymerlipid hybrid nanoparticles. J Contr Rel. 2008; 1: 60-70. https://doi.org/10.1016/j.jconrel.2008.02.014
Shah P, Desai P, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Contr Rel. 2012; 158: 336-345. https://doi.org/10.1016/j.jconrel.2011.11.016
Agrawal U, Gupta M, Vyas SP. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artif Cells Nanomed Biotechnol. 2013; 23:456-460.
Ranjan OP, Shavi GV, Nayak UY, Arunuqam K, Averineni RK, et al., Controlled release chitosan microspheres of mirtazapine: in vitro and in vivo evaluation. Arch Pharm Res. 2011; 11:1919-1929. https://doi.org/10.1007/s12272-011-1112-1
Babu RJ, Kanikkannan N, Kikwai L, Ortega C, Andega S, et al., The influence of various methods of cold storage of skin on the permeation of melatonin and nimesulide. J Control Rel. 2003; 86: 49-57. https://doi.org/10.1016/S0168-3659(02)00368-1
P. Zhao, H. Wang, M. Yu, Z. Liao, X. Wang, et al., Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: In vitro and in vivo evaluation, Eur. J. Pharm. Biopharm. 2012; 81:248e256. https://doi.org/10.1016/j.ejpb.2012.03.004
Ling G, Zhang P, ZhangW, Sun J, Meng X, et al., Development of novel self assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Contr Rel. 2010; 148:241-248. https://doi.org/10.1016/j.jconrel.2010.08.010
Rajak H, Jain DK, Dewangan PK, Patel V, Agrawal N. Application of microwaves in organic synthesis: speeding up the process of drug discovery. RGUHS J. Pharm. Sci. 2013; 3(1):14-20.
Jubie S, Rajeshkumar R, Yellareddy B, Siddhartha G, Sandeep M, et al., Microwave assisted synthesis of some novel benzimidazole substituted Fluoroquinolones and their antimicrobial evaluation. J Pharmaceu Sci Res. 2010; 2:69-76.
ICH Q1A (R2), Stability Testing of New Drug Substances and Products, International Conference on Harmonization, U.S. Department of Health and Human Service Food and Drug Administration, 2003, pp. 4e20. CPMP/ICH/2736/99.
Bose RJC, Ravikumar R, Karuppagounder V, Bennet D, Rangasamy S, Thandavarayan RA. Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges. Drug Discov Today. 2017; 22(8):1258-65. https://doi.org/10.1016/j.drudis.2017.05.015
Chaudhary K, Parihar S, Sharma D, A critical review on nanoscience advancement: in treatment of viral infection, Journal of Drug Delivery and Therapeutics. 2011; 11(6):225-237 https://doi.org/10.22270/jddt.v11i6.5030
Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, Wood GC. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013; 9(4):474-91. https://doi.org/10.1016/j.nano.2012.11.010
Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic Moreno AF, Alexis F, Langer R, Farokhzad OC. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2(8):1696-702. https://doi.org/10.1021/nn800275r
Chu CH, Wang YC, Huang HY, Wu LC, Yang CS. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications. Nanotechnology. 2011; 22(18):185601. https://doi.org/10.1088/0957-4484/22/18/185601
Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm. 2012; 424(1-2):98-106. https://doi.org/10.1016/j.ijpharm.2011.12.045
Shah J, Patel S, Bhairy S, Hirlekar R. Formulation optimization, characterization and in vitro anti-cancer activity of curcumin loaded nanostructured lipid carriers. Int J Curr Pharm Sci. 2022; 14(1):31-43. https://doi.org/10.22159/ijcpr.2022v14i1.44110
Ebos JML, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009; 15(16):5020-5. https://doi.org/10.1158/1078-0432.CCR-09-0095
El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Contr Rel. 2004; 94(1):1-14. https://doi.org/10.1016/j.jconrel.2003.09.013
Jain S, Purohit A, Nema P, Vishwakarma H, Qureshi A, Jain PK. Pathways of targeted therapy for colorectal cancer. J Drug Deliv Ther.2022; 12(5):217-221. https://doi.org/10.22270/jddt.v12i5.5602
Bivas Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. European J Pharm Biopharm. 2004; 58(1):1-6. https://doi.org/10.1016/j.ejpb.2004.03.008
Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res. 2005; 22(1):1-10. https://doi.org/10.1007/s11095-004-9003-5
Zhong Q, Chinta DM, Pamujula S, Wang H, Yao X, Mandal TK, Luftig RB. Optimization of DNA delivery by three classes of hybrid nanoparticle/DNA complexes. J Nanobiotechnol. 2010; 8(1):6. https://doi.org/10.1186/1477-3155-8-6
Mieszawska AJ, Gianella A, Cormode DP, Zhao Y, Meijerink A, Langer R, Farokhzad OC, Fayad ZA, Mulder WJ. Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb). 2012; 48(47):5835-7. https://doi.org/10.1039/c2cc32149a
Purohit A, Jain S, Nema P, Vishwakarma H, Jain PK. Intelligent or smart polymers: advance in novel drug delivery. J Drug Deliv Ther. 2022; 12(5):208-216. https://doi.org/10.22270/jddt.v12i5.5578
Published
Abstract Display: 1328 
PDF Downloads: 1115 PDF Downloads: 192 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.